TREK channel activation suppresses migraine pain phenotype
Send a publication request

Publication request

Thank you for your interest in our product range and your request for this publication, which will be sent to you if the research team and the journal allow it. Our commercial team will contact you as soon as possible.

- Categories : Orofacial pain , Publications - ID: 1471

PA Prado, A Landra-Willm, C Verkest et al

Universite Co te dÕAzur, CNRS, INSERM, iBV, Nice, France


Activation and sensitization of trigeminal ganglia (TG) sensory neurons, leading to the release of pro inflammatory peptides such as calcitonin gene-related pep tide (CGRP), are likely a key component in migraine-related headache induction. Reducing TG neuron excitability represents therefore an attractive alternative strategy to relieve migraine pain. Here by using pharmacology and genetic invalidation ex vivo and in vivo, we demonstrate that activating TREK1 and TREK2 two-pore-domain potassium (K2P) channels inhibits TG neuronal firing sufficiently to fully reverse the migraine-like phenotype induced by NO-donors in rodents. Finally, targeting TREK is as efficient as treatment with CGRP antagonists, which represents one of the most effective migraine therapies. Altogether, our results demonstrate that inhibiting TG excitability by pharmacological activation of TREK channels should be considered as an alternative to the current migraine

BIOSEB Instruments Used:
Von Frey Filaments (Bio-VF-M)

Related products

Share this content